[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Didanosine Enteric-Coated Capsule

Current Role in Patients with HIV-1 Infection

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Didanosine, which is a synthetic nucleoside analogue intracellularly phosphorylated to the active metabolite, inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate. Currently, didanosine is mainly provided as an enteric-coated capsule. In vitro, the molecule is active against laboratory strains and clinical isolates of HIV-1 in resting and activated T cells and monocyte/macrophages. Didanosine may select for resistance mutations that may render the drug inactive against the virus; L74V and K65R remain as the main didanosine-related mutations. In vitro, phenotypic susceptibility to didanosine was decreased beyond a defined fold change clinical cut-off (1.7), and it is considered that genotypic resistance exists when five thymidine-associated mutations or four plus M184V are present. In vivo, clinical studies have shown that didanosine retains significant antiviral activity in patients who have up to five nucleoside analogue mutations at baseline. Didanosine is useful in patients with no previous therapy, as well as in experienced patients in whom one or more antiretroviral regimens has failed.

Enteric-coated didanosine is taken once daily, its co-administration with food has been recently evaluated and a reduction of the efficacy of the antiretroviral treatment was not observed. Administered with lamivudine (or emtricitabine), it can be considered a good alternative for use in the nucleoside analogue backbone included in combination therapies for antiretroviral-naive patients. Didanosine could be used in initial treatments for patients intolerant of zidovudine, abacavir or tenofovir. It can be included in once-daily combination regimens, which are more convenient and patient friendly.

Prospective, observational and open-label studies, as well as clinical trials (with durations between 24 and 96 weeks), have demonstrated the safety and efficacy of didanosine plus lamivudine (or emtricitabine) plus efavirenz (or nevirapine) in previously untreated HIV-1-infected patients. The administration of didanosine to treatment-experienced patients has been evaluated in two different contexts: patients in whom previous therapies have failed (rescue therapy) and those with controlled viraemia who are switched to a didanosine-containing regimen for simplification.

Adverse events associated with the administration of didanosine have been well known since the initial clinical trials with the drug. Gastrointestinal intolerance, peripheral neuropathy and hyperamylasaemia/pancreatitis were the most frequently reported. In the highly active antiretroviral therapy (HAART) era, the rate of adverse events has decreased. The tolerability of didanosine has been clearly improved with the development of the enteric-coated capsule. Severe manifestations of mitochondrial toxicity, including lactic acidosis and abnormal fat distribution, are rare complications, and occur most frequently when didanosine is used in combination with stavudine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. BMS. VIDEX® EC (didanosine) delayed-release capsules enteric-coated beadlets. Structured product labeling [online]. Available from URL: http://www.fda.gov/cder/foi/label/2001/videxec.pdf [Accessed 2006 Oct 20]

  2. Yao SY, Ng AM, Sundaram M, et al. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001 Apr–Jun; 18: 161–7

    Article  PubMed  CAS  Google Scholar 

  3. Alhuwalia G, Cooney D, Mitsuya H, et al. Initial studies of the cellular pharmacology of 2′,3′-dideoxinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987 Nov 15; 36: 3797–800

    Article  Google Scholar 

  4. Faulds D, Brogden RN. Didanosine a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992 Jul; 44: 94–116

    Article  PubMed  CAS  Google Scholar 

  5. Perry CM, Balfour JA. Didanosine: an update on its antiviral activity, pharmacokinetic properties an therapeutic efficacy on the management of HIV disease. Drugs 1996 Dec; 52: 928–62

    Article  PubMed  CAS  Google Scholar 

  6. Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs 1999 Dec; 58: 1099–135

    Article  PubMed  CAS  Google Scholar 

  7. Damle BD, Kaul S, Behr D, et al. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol 2002 Jul; 42: 791–7

    Article  PubMed  CAS  Google Scholar 

  8. Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 2002 Apr; 42: 419–27

    Article  PubMed  CAS  Google Scholar 

  9. Girard P, Benech H, Gendron A, et al. Food Effect on the intracellular (IC) pharmacokinetics of dideoxyadenosine triphosphate (ddA-TP), the active metabolite of didanosine (ddI), in treated HIV-1 infected patients [poster H-1900]. 45th ICAAC; 2005 Dec 16–19; Washington DC

  10. Ahluwalia G, Cooney DA, Hartman NR, et al. Anomalous accumulation and decay of 2′,3′-dideoxyadenosine-5′-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2′,3′-dideoxyinosine. Drug Metab Dispos 1993 Mar–Apr; 21: 369–76

    PubMed  CAS  Google Scholar 

  11. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001 Dec; 6: 249–53

    PubMed  CAS  Google Scholar 

  12. Reynes J, Denisi R, Massip P, et al. Once-daily administration of didanosine in combination with d4T in antiretroviral-naïve patients: the STADI Group. J Acquir Immune Defic Syndr 1999 Sep 1; 22: 103–5

    Article  PubMed  CAS  Google Scholar 

  13. López JC, Moreno S, Jiménez-Oñate F, et al. A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine entericcoated capsules (FOODDIe study). HIV Clin Trials 2006 Jul–Aug; 7: 155–62

    Article  PubMed  Google Scholar 

  14. Sánchez-Conde M, Asensi V, Sanz J, et al. Efficacy and safety of a QD regimen (didanosine, lamivudine and efavirenz) as initial therapy in HIV-infected patients [abstract WePe12.2C27]. Third IAS conference; 2005 Jul 24–27; Rio de Janeiro

  15. Moreno S, Antela A, Gutiérrez C, et al. A pilot, comparative study of the antiviral activity of didanosine monotherapy administered with and withoutfood [abstract P301]. Eighth International Congress on Drug Therapy in HIV Infection; 2006 Nov 12–16; Glasgow

  16. Berenguer J, Ribera E, Domingo P, et al. GESIDA 3903 team. Didanosine, lamivudine and efavirenz vs zidovudine, lamivudine and efavirenz, for initial treatment of HIV infection: planned 24-week analysis of a prospective randomized noninferiority clinical trial, GESIDA 39/03 [abstract 504]. 14th Conference on Retroviruses and Opportunistic Infections. 2007 Feb 25–28; Los Angeles (CA)

  17. Lotterer E, Ruhnke M, Trautmann M, et al. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991; 40: 305–8

    Article  PubMed  CAS  Google Scholar 

  18. Ruhnke M, Bauer FE, Seifert M, et al. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993 Oct; 37: 2153–8

    Article  PubMed  CAS  Google Scholar 

  19. Nazareno LA, Holazo AA, Limjuco R, et al. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1995 Oct; 12: 1462–5

    Article  PubMed  CAS  Google Scholar 

  20. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004 Apr; 48: 1089–95

    Article  PubMed  CAS  Google Scholar 

  21. Shelton MJ, O’Donnell AM, Morse GD. Didanosine. Ann Pharmacother 1992 May; 26: 660–70

    PubMed  CAS  Google Scholar 

  22. Damle BD, Mummaneni V, Kaul S, et al. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 2002 Feb; 46: 385–91

    Article  PubMed  CAS  Google Scholar 

  23. la Porte C, Verweij-van Wissen C, van Ewijk N, et al. Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. J Clin Pharmacol 2005 Feb; 45: 211–8

    Article  PubMed  Google Scholar 

  24. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: a working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 10, 2006 [online]. Available from URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2006 Oct 20]

  25. Bruce RD, Altice FL, Gourevitch MN, et al. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006 Apr; 41: 563–72

    Article  PubMed  CAS  Google Scholar 

  26. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 2005 Dec; 45: 1360–7

    Article  PubMed  CAS  Google Scholar 

  27. Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005 Mar 24; 19: 569–75

    Article  PubMed  CAS  Google Scholar 

  28. Lacombe K, Pacanowski J, Meynard JL, et al. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose containing highly active antiretroviral therapy regimen. AIDS 2005 Jul 1; 19: 1107–8

    Article  PubMed  CAS  Google Scholar 

  29. Negredo E, Bonjoch A, Paredes R, et al. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis 2005 Sep 15; 41: 901–5

    Article  PubMed  CAS  Google Scholar 

  30. Karrer U, Ledergerber B, Weber R, et al. No evidence for poor immunologic response in patients treated with a combination of tenofovir and didanosine at 250mg daily [abstract 588]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  31. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001 Jan 27; 357: 280–1

    Article  PubMed  CAS  Google Scholar 

  32. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, et al. Mitochondrial toxic effects and ribavirin. Lancet 2001 Jun 2; 357: 1803–4

    Article  PubMed  CAS  Google Scholar 

  33. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 2006; 44 (1 Suppl.): S119–25

    Article  PubMed  CAS  Google Scholar 

  34. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004 Feb; 9: 133–8

    PubMed  CAS  Google Scholar 

  35. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006 Aug–Sep; 14: 125–30

    PubMed  Google Scholar 

  36. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994 Aug 15; 121: 263–8

    PubMed  CAS  Google Scholar 

  37. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991 Sep 27; 253: 1557–9

    Article  Google Scholar 

  38. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994 Apr; 169: 722–9

    Article  PubMed  CAS  Google Scholar 

  39. Winters MA, Shafer RW, Jellinger RA, et al. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997 Apr; 41: 757–62

    PubMed  CAS  Google Scholar 

  40. Molina JM, Marcelin AG, Pavie J, et al. AI454-176 Jaguar Study Team. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis 2005 Mar 15; 191: 840–7

    CAS  Google Scholar 

  41. Marcelin AG, Flandre P, Pavie J, et al. AI454-176 Jaguar Study Team. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005 May; 49: 1739–44

    CAS  Google Scholar 

  42. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004 Jan; 72: 162–5

    Article  PubMed  CAS  Google Scholar 

  43. Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003 Oct 1; 188: 992–1000

    Article  PubMed  CAS  Google Scholar 

  44. Blanco JL, Biglia A, De Lazzari E, et al. Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations. AIDS 2006 Sep 11; 20: 1891–2

    Article  PubMed  CAS  Google Scholar 

  45. Sproat M, Pozniak AL, Peeters M, et al. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther 2005; 10: 357–61

    PubMed  CAS  Google Scholar 

  46. Romano L, Venturi G, Bloor S, et al. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 2002 April; 185: 898–904

    Article  PubMed  CAS  Google Scholar 

  47. Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000 Jul 28; 14: 1601–10

    Article  PubMed  CAS  Google Scholar 

  48. Carr A, Chuah J, Hudson J, et al. A randomized, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000 Jun 16; 14: 1171–80

    Article  PubMed  CAS  Google Scholar 

  49. French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials 2002 May–Jun; 3: 177–85

    Article  PubMed  Google Scholar 

  50. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003 May 2; 17: 987–99

    Article  PubMed  Google Scholar 

  51. Sanne I, Piliero P, Squires K, et al. for the AI424-007 Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr 2003 Jan 1; 32: 18–29

    CAS  Google Scholar 

  52. Saag MS, Cahn P, Raffi F, et al. FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. JAMA 2004 Jul 14; 292: 180–90

    CAS  Google Scholar 

  53. Robbins GK, De Gruttola V, Shafer RW, et al. AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 Dec 11; 349: 2293–303

    CAS  Google Scholar 

  54. Amin J, Moore A, Carr A, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitors backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003 Jul–Aug; 4: 252–61

    Article  PubMed  CAS  Google Scholar 

  55. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003 Sep 26; 17: 2045–52

    Article  PubMed  CAS  Google Scholar 

  56. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection. 2006 Recommendations of the International AIDS Society-USA Panel. JAMA Aug 16 2006; 296: 827–43

    CAS  Google Scholar 

  57. Staszewski S, Haberl A, Gute P, et al. Nevirapine/didanosine/ lamivudine once-daily in HIV-infected intravenous drug users. Antivir Ther 1998; 3 Suppl. 4: 55–6

    PubMed  CAS  Google Scholar 

  58. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus infected patients. J Infect Dis 2000 Aug; 182: 599–602

    Article  PubMed  CAS  Google Scholar 

  59. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naïve HIV-1-infected patients. Antivir Ther 2003 Aug; 8: 339–46

    PubMed  CAS  Google Scholar 

  60. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatmen-naïve HIV-1-infected adults in Senegal. AIDS 2003 May 2; 17: 1017–22

    Article  PubMed  CAS  Google Scholar 

  61. Santos J, Palacios R, López M, et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine and efavirenz in naïve patients: the VESD study. HIV Clin Trials 2005 Nov–Dec; 6: 320–8

    Article  PubMed  CAS  Google Scholar 

  62. DeJesus E, Ward D, Cohen C, et al. Efficacy and safety of a once-daily efavirenz-based regimen for treatment naïve HIV subjects: 96-week results from the DART I Trial [abstract PE7.3/3]. Tenth European AIDS Conference/The European AIDS Clinical Society; 2005 Nov 17–20; Dublin

  63. Ribera E, Rodríguez-Pardo D, Rubio M, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naïve HIV-infected patients. Antivir Ther 2005; 10: 605–14

    PubMed  CAS  Google Scholar 

  64. Winters MA, Bosch RJ, Albrech MA, et al. ACTG 364 study team. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J Infect Dis 2003 Aug 15; 188: 537–40

    PubMed  CAS  Google Scholar 

  65. Stebbing J, Nelson M, Orkin C, et al. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). J Antimicrob Chemother 2004 Mar; 53: 501–5

    Article  PubMed  CAS  Google Scholar 

  66. Cozzi-Lepri A, Ruiz L, Loveday C, et al. EuroSIDA Study Group. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10: 791–802

    CAS  Google Scholar 

  67. Capdepont S, Aurillac-Lavignolle V, Faure M, et al. An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients. J Clin Virol 2006 May; 36: 36–42

    Article  PubMed  CAS  Google Scholar 

  68. Hernández B, Moreno S, Pérez-Elías MJ, et al. Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients. J Acquir Immune Defic Syndr 2006; 15: 43: 556–9

    PubMed  Google Scholar 

  69. Pérez-Elías MJ, Moreno S, Gutiérrez C, et al. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS 2005 Apr 29; 19: 695–8

    Article  PubMed  Google Scholar 

  70. Negredo E, Moltó J, Muñoz-Moreno JA, et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther 2004 Jun; 9: 335–42

    PubMed  CAS  Google Scholar 

  71. Dybul M, Nies-Kraske E, Dewar R, et al. A proof-of-concept study of short-cycle intermitent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004 Jun 1; 189: 1974–82

    Article  PubMed  CAS  Google Scholar 

  72. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996 Oct 10; 335: 1081–90

    Article  PubMed  CAS  Google Scholar 

  73. Kunches L, Einhalter N, Marquis A, et al. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. J Acquir Immune Defic Syndr 2001 Oct 1; 28: 150–3

    PubMed  CAS  Google Scholar 

  74. Brinkman K, Hofsted HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998 Oct 1; 12: 1735–44

    Article  PubMed  CAS  Google Scholar 

  75. Kelleher T, Cross A, Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomised clinical trials including didanosine. Clin Ther 1999 Jul; 21: 1182–92

    Article  PubMed  CAS  Google Scholar 

  76. Lafeuillade A, Aubert L, Chaffanjon P, et al. Optic neuritis associated with dideoxyinosine. Lancet 1991 Mar 9; 337: 615–6

    Article  PubMed  CAS  Google Scholar 

  77. Falco V, Rodríguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficinecy virus infected patients: report of 12 cases and review of the literatura. Clin Infect Dis 2002 Mar 15; 34: 838–46

    Article  PubMed  Google Scholar 

  78. Lonergan J, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combinations regimens. Clin Infect Dis 2000 Jul; 31: 162–6

    Article  PubMed  CAS  Google Scholar 

  79. Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003 Nov; 17: 2495–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have declared that no sources of funding were used to assist in the preparation of this review and that they have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Ramón y Cajal Hospital, Alcalá University, Madrid, Spain

    Santiago Moreno, Beatriz Hernández & Fernando Dronda

Authors
  1. Santiago Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beatriz Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando Dronda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Santiago Moreno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreno, S., Hernández, B. & Dronda, F. Didanosine Enteric-Coated Capsule. Drugs 67, 1441–1462 (2007). https://doi.org/10.2165/00003495-200767100-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767100-00006

Keywords

Search

Navigation